Title:
抗－Ｂ７－Ｈ３抗体およびその用途
Document Type and Number:
Japanese Patent JP7150880
Kind Code:
B2
Abstract:
Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.
More Like This:
Inventors:
Park, Kyungsoo
Lee, Yang Sung
Jeon, Hye Jin
Yun, Wiyun
Song Young Kyu
ha, sang yoon
Kim, Miyoung Joon
Park, Eunyang
Park, Kyung Jin
Sun, Unsil
Kim, Yeon Joo
Ann, Chihyun
Sun, Byungjae
Song, Taehe
Park, Young Tong
Lee, Yang Sung
Jeon, Hye Jin
Yun, Wiyun
Song Young Kyu
ha, sang yoon
Kim, Miyoung Joon
Park, Eunyang
Park, Kyung Jin
Sun, Unsil
Kim, Yeon Joo
Ann, Chihyun
Sun, Byungjae
Song, Taehe
Park, Young Tong
Application Number:
JP2020564922A
Publication Date:
October 11, 2022
Filing Date:
May 24, 2019
Export Citation:
Assignee:
ABL Bio Incorporated
International Classes:
C12N15/13; A61K39/395; A61P35/00; A61P37/04; C07K16/28; C07K16/46; G01N33/531; G01N33/574
Domestic Patent References:
| JP2013520994A |
Foreign References:
| WO2012147713A1 |
Attorney, Agent or Firm:
Sonoda & Kobayashi Patent Attorneys Corporation